Which treatment option represents first-line therapy for mild to moderate plaque psoriasis?

Which treatment option represents first-line therapy for mild to moderate plaque psoriasis?

• A. Topical corticosteroids
• B. Calcipotriene
• C. Topical coal tar
• D. Phototherapy

Answer: (D)

The main concept is how we approach treatment for mild to moderate plaque psoriasis. When the disease is limited to a few patches or smaller areas, starting with topical therapy is preferred because it targets the skin directly, provides rapid relief, and avoids systemic exposure. Topical corticosteroids are typically the first-line choice because they quickly reduce inflammation and suppress the overactive skin cell growth that drives plaque formation. They’re effective for shrinking plaques, itching, and redness, with a relatively straightforward dosing plan. Calcipotriene, a vitamin D analog, is another common option for first-line use; it helps normalize skin cell proliferation and can be used alone or together with a steroid to enhance effect and reduce steroid-related side effects over time. In many patients, a regimen that uses a potent topical steroid or a steroid-calcipotriene combination achieves good control with manageable safety. Phototherapy uses ultraviolet light to slow skin turnover and reduce inflammation and can be highly effective, but it’s generally reserved for more extensive disease or when topical therapy isn’t practical or has failed. It requires regular clinic visits and carries risks such as sun sensitivity and potential long-term skin damage with prolonged exposure. Because of these factors, phototherapy is not usually the first-line option for mild disease confined to smaller areas. So, for mild to moderate plaque psoriasis, the best initial approach is topical therapy, especially topical corticosteroids (with or without calcipotriene), reserving phototherapy for broader or more persistent disease.

The main concept is how we approach treatment for mild to moderate plaque psoriasis. When the disease is limited to a few patches or smaller areas, starting with topical therapy is preferred because it targets the skin directly, provides rapid relief, and avoids systemic exposure.

Topical corticosteroids are typically the first-line choice because they quickly reduce inflammation and suppress the overactive skin cell growth that drives plaque formation. They’re effective for shrinking plaques, itching, and redness, with a relatively straightforward dosing plan. Calcipotriene, a vitamin D analog, is another common option for first-line use; it helps normalize skin cell proliferation and can be used alone or together with a steroid to enhance effect and reduce steroid-related side effects over time. In many patients, a regimen that uses a potent topical steroid or a steroid-calcipotriene combination achieves good control with manageable safety.

Phototherapy uses ultraviolet light to slow skin turnover and reduce inflammation and can be highly effective, but it’s generally reserved for more extensive disease or when topical therapy isn’t practical or has failed. It requires regular clinic visits and carries risks such as sun sensitivity and potential long-term skin damage with prolonged exposure. Because of these factors, phototherapy is not usually the first-line option for mild disease confined to smaller areas.

So, for mild to moderate plaque psoriasis, the best initial approach is topical therapy, especially topical corticosteroids (with or without calcipotriene), reserving phototherapy for broader or more persistent disease.